DGAP-News

B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN proposes Supervisory Board candidates for election at its Annual General Meeting

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): AGM/EGM/Change of Personnel B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN proposes Supervisory Board candidates for election at its Annual General Meeting 31.01.2017 / 14:30 The issuer is solely responsible for the content of this announcement. BRAIN proposes Supervisory Board candidates for election at its Annual General Meeting

Zwingenberg, January 31, 2017: Today, B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG", ISIN DE0005203947 / WKN 520394) has published the invitation for its first public Annual General Meeting as a stock listed company, to be held on March 9, 2017, to its shareholders in the electronic Federal Gazette (Bundesanzeiger) and on its website. Besides other agenda items, four of the six Supervisory Board members of BRAIN AG are to be newly elected during the General Meeting. While the term of office of Professor Klaus-Peter Koller and Dr Holger Zinke regularly ends with the end of the upcoming General Meeting, the Supervisory Board members Siegfried Drueker and Dr Matthias Kromayer resign from their positions. In addition to the re-election of the long-term Supervisory Board member Professor Dr Klaus-Peter Koller, three new Supervisory Board candidates are proposed for election to the Annual General Meeting.

The three new candidates are Dr Anna Eichhorn, Dr Martin Jager and Dr Georg Kellinghusen. In selecting these three, the Supervisory Board has paid particular attention to continuity, experience and necessary expertise, with an additional focus on the indispensable industry, specialist and business knowledge of the candidates, which are essential for the exercise of the impending Supervisory Board mandates.

Dr Anna Eichhorn is an entrepreneur in the field of molecular diagnostics and a proven specialist in the translation of data on human genetics into the development of active ingredients. Dr Martin Jager has extensive and long-standing international experience in the development and marketing of new natural products and food ingredients. The expertise of Dr Georg Kellinghusen as a recognised financial expert is based on his 30 years of CFO work in various listed companies as well as his former membership in the Supervisory Board of BRAIN AG. Furthermore, Professor Dr Klaus-Peter Koller with his industrial expertise at the interface of research, development and production of new biological products will continue to benefit BRAIN.